Comments on: Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer

Comments on: Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer https://9krapalm.com/dizals-zegfrovy-sunvozertinib-new-drug-application-accepted-and-granted-priority-review-by-china-national-medical-products-administration-for-first-line-treatment-of-egfr-exon-20-insertion-m/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Wed, 27 May 2026 11:49:02 +0000 hourly 1 https://wordpress.org/?v=6.9.4